1H-Imidazole-5-carboxamide, 4-(1H-benzimidazol-2-yl)-N-cyclohexyl- manufacturers
- Autophagy-IN-2
-
- $1520.00
-
2026-05-11
- CAS:2755454-90-9
- Purity:
- Supply Ability: 10g
|
| | 1H-Imidazole-5-carboxamide, 4-(1H-benzimidazol-2-yl)-N-cyclohexyl- Basic information |
| | 1H-Imidazole-5-carboxamide, 4-(1H-benzimidazol-2-yl)-N-cyclohexyl- Chemical Properties |
| density | 1.34±0.1 g/cm3(Predicted) | | pka | 9.89±0.10(Predicted) |
| | 1H-Imidazole-5-carboxamide, 4-(1H-benzimidazol-2-yl)-N-cyclohexyl- Usage And Synthesis |
| Uses | Autophagy-IN-2 (Compound 7h) is an autophagic flux inhibitor. Autophagy-IN-2 induces cancer cell apoptosis and can be used for triple-negative breast cancer research[1]. | | in vivo | Autophagy-IN-2 (Compound 7h) (5 and 15 mg/kg; i.p.; every 3 days for 3 weeks) suppresses tumor growth in a dose-dependent manner[1]. | Animal Model: | Six-week-old female NOD/SCID mice, MDA-MB-231 xenograft[1] | | Dosage: | 5 mg/kg, 15 mg/kg | | Administration: | Intraperitoneal injection, every 3 days for 3 weeks | | Result: | Suppressed human TNBC tumor growth in a dose-dependent manner and resulted in a concentration-dependent upregulation of LC3B-II, p62, γH2AX and PARP. |
| | References | [1] Yang DL, et al. Discovery of fused benzimidazole-imidazole autophagic flux inhibitors for treatment of triple-negative breast cancer. Eur J Med Chem. 2022 Jun 26;240:114565. DOI:10.1016/j.ejmech.2022.114565 |
| | 1H-Imidazole-5-carboxamide, 4-(1H-benzimidazol-2-yl)-N-cyclohexyl- Preparation Products And Raw materials |
|